Coralville, IA ; 03/13/2020
Amount Funded: $11 Million
Type: Series C
Lead Investor: First Analysis Corporation
Participating Investor(s): Blue Heron Capital, Unity Point Health Ventures, Next Level Ventures, Chartline Capital Partners, Rural Vitality Fund, Rittenhouse Ventures, Iowa First Capital Fund, Angels Forum
Company Description: VIDA provides the new standard of pulmonary care by using AI-powered CT imaging software and services to aid the early detection, evaluation, and treatment planning of patients with or at risk of lung diseases, including emphysema and airway obstructive diseases (COPD), asthma, interstitial lung disease, and lung cancer.
What funding will be used for: ” VIDA will use the funds to address market deficits in the early assessment, monitoring, and treatment of lung disease by accelerating the commercialization of its leading LungPrin® solution suite and by expanding LungPrint’s clinical portfolio.”
“We are driven to continuously raise the standard of care for patients with or at risk of lung disease. By equipping care teams with LungPrint, patient care and quality of life can be positively affected. VIDA is endlessly thankful for the extensive support of the people, resources, and programs from the State of Iowa leading to this expansive funding. VIDA can now accelerate LungPrint’s market access, further connecting its benefits to the many millions of patients with lung disease.”
-Susan A. Wood, PhD, CEO, VIDA
Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.